Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes
Diabetic Medicine · 2026
DOI: 10.1111/dme.70247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetic Medicine, 2026. Verfasst von J K Ward und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiorenal Team, Diabetes, Metabolism & Inflammation Group, College of Health and Science, Joseph Banks Laboratories, University of Lincoln, Lincoln…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Eicosapentaenoic Acid, Inflammation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amarin Corporation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Despite intensive lipid‐lowering therapy, individuals with atherosclerotic cardiovascular disease (ASCVD) exhibit residual inflammatory risk, which drives recurrent cardiovascular events. This risk is amplified in type 2 diabetes mellitus (T2DM), where a pro‐inflammatory milieu accelerates atherogenesis. Monocyte‐derived macrophages (MDMs), key mediators of vascular inflammation, contribute significantly to this process. Icosapent ethyl (IPE), a highly purified ethyl ester of eicosapentaenoic acid (EPA), reduces major adverse cardiovascular events (MACE) beyond triglyceride lowering, yet its cellular mechanisms remain unclear. This study aims to determine whether IPE modulates inflammatory pathways in patient‐derived MDMs and to distinguish direct EPA effects from therapy‐mediated changes.
Methods
This single‐centre, open‐label, randomised observational cohort study will recruit ASCVD patients, stratified by T2DM status, who are prescribed IPE (Vazkepa®). MDMs and plasma/serum samples will be collected from patients, either IPE‐naïve or following 6 months of therapy. In parallel, direct EPA effects will be assessed by treating MDMs from healthy donors and ASCVD patients with physiologically relevant concentrations of EPA. We will evaluate NOD‐like receptor protein 3 (NLRP3) inflammasome priming and activation, inflammatory cytokine profiles, and markers of cellular senescence.
Results
The study will investigate mechanisms that potentially underlie the cardiovascular benefits of IPE, focusing on the modulation of inflammatory pathways. We hypothesise that IPE attenuates priming and activation of the NLRP3 inflammasome in monocyte‐derived macrophages, thereby reducing cellular inflammation and senescence.
Conclusions
This study will provide mechanistic insight into how IPE influences macrophage‐driven inflammation in ASCVD and T2DM, informing strategies to target residual inflammatory risk in high‐risk cardiometabolic populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiorenal Team, Diabetes, Metabolism & Inflammation Group, College of Health and Science, Joseph Banks Laboratories, University of Lincoln, Lincoln, UK.
- Lincolnshire Heart Centre, United Lincolnshire Hospitals, Lincoln, UK.
- Cardiology Department, Hull University Teaching Hospitals, Hull, UK.
ORCID-Profile: J K Ward, P E Squires
Förderung
- Amarin Corporation
Zitieren
APA
Ward, J. K., Shah, M. U., Lee, K., Squires, P. E., & Hills, C. E. (2026). Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes. Diabetic Medicine. https://doi.org/10.1111/dme.70247
Vancouver
Ward JK, Shah MU, Lee K, Squires PE, Hills CE. Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes. Diabetic Medicine. 2026. doi:10.1111/dme.70247
BibTeX
@article{Ward2026,
author = {Ward, J K and Shah, M U and Lee, K and Squires, P E and Hills, C E},
title = {Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes},
journal = {Diabetic Medicine},
year = {2026},
doi = {10.1111/dme.70247}
}
EUVIMED